The emerging role of the Hippo pathway in lung cancers

Clinical implications

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Background: The incidence of lung cancers has increased globally. Increased exposure to tobacco, passive smoking, less consumption of vegetables and fruits and occupational exposure to asbestos, arsenic and chromium are the main risk factors. The pathophysiology of lung cancer is complex and not well understood. Various microRNAs, genes and pathways are associated with lung cancers. The genes involved in lung cancers produce proteins involved in cell growth, differentiation, different cell cycles, apoptosis, immune modulation, tumor spread and progression. The Hippo pathway (also known as the Salvador-Warts-Hippo pathway) is the latest emerging concept in cancers. The Hippo pathway plays an important role in controlling the size of the tissue and organ by virtue of its action on cell proliferation and apoptosis. Objective: In the present review, we highlight the mammalian Hippo pathway, role of its core members, its upstream regulators, downstream effectors and the resistance cases in lung cancers. Results: Specific interaction of Mer with cell surface hyaluronan receptor CD44 is vital in cell contact inhibition, thereby activating Hippo pathway. Both transcription co-activators YAP and TAZ (also known as WWTR1, being homologs of Drosophila Yki) are important regulators of proliferation and apoptosis, and serve as major downstream effectors of the Hippo pathway. Mutation of NF2, the upstream regulator of Hippo pathway is linked to the cancers. Conclusion: Targeting YAP and TAZ may be important for future drug delivery and treatment.

Original languageEnglish
Pages (from-to)1880-1892
Number of pages13
JournalCurrent Drug Targets
Volume18
Issue number16
DOIs
Publication statusPublished - 1 Dec 2017

Fingerprint

Lung Neoplasms
Apoptosis
Genes
CD44 Antigens
Drug therapy
Tobacco
Asbestos
Vegetables
Cell proliferation
Cell growth
Arsenic
Chromium
Transcription
Fruits
MicroRNAs
Drug delivery
Tumors
Contact Inhibition
Neoplasms
Tobacco Smoke Pollution

Keywords

  • Apoptosis
  • Cell proliferation
  • Drug delivery
  • Genes
  • Hippo pathway
  • Lung cancer

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Cite this

The emerging role of the Hippo pathway in lung cancers : Clinical implications. / Teoh, Seong Lin; Das, Srijit.

In: Current Drug Targets, Vol. 18, No. 16, 01.12.2017, p. 1880-1892.

Research output: Contribution to journalReview article

@article{90f9aaade2b04be4b0f171d10d7544dc,
title = "The emerging role of the Hippo pathway in lung cancers: Clinical implications",
abstract = "Background: The incidence of lung cancers has increased globally. Increased exposure to tobacco, passive smoking, less consumption of vegetables and fruits and occupational exposure to asbestos, arsenic and chromium are the main risk factors. The pathophysiology of lung cancer is complex and not well understood. Various microRNAs, genes and pathways are associated with lung cancers. The genes involved in lung cancers produce proteins involved in cell growth, differentiation, different cell cycles, apoptosis, immune modulation, tumor spread and progression. The Hippo pathway (also known as the Salvador-Warts-Hippo pathway) is the latest emerging concept in cancers. The Hippo pathway plays an important role in controlling the size of the tissue and organ by virtue of its action on cell proliferation and apoptosis. Objective: In the present review, we highlight the mammalian Hippo pathway, role of its core members, its upstream regulators, downstream effectors and the resistance cases in lung cancers. Results: Specific interaction of Mer with cell surface hyaluronan receptor CD44 is vital in cell contact inhibition, thereby activating Hippo pathway. Both transcription co-activators YAP and TAZ (also known as WWTR1, being homologs of Drosophila Yki) are important regulators of proliferation and apoptosis, and serve as major downstream effectors of the Hippo pathway. Mutation of NF2, the upstream regulator of Hippo pathway is linked to the cancers. Conclusion: Targeting YAP and TAZ may be important for future drug delivery and treatment.",
keywords = "Apoptosis, Cell proliferation, Drug delivery, Genes, Hippo pathway, Lung cancer",
author = "Teoh, {Seong Lin} and Srijit Das",
year = "2017",
month = "12",
day = "1",
doi = "10.2174/1389450117666160907153338",
language = "English",
volume = "18",
pages = "1880--1892",
journal = "Current Drug Targets",
issn = "1389-4501",
publisher = "Bentham Science Publishers B.V.",
number = "16",

}

TY - JOUR

T1 - The emerging role of the Hippo pathway in lung cancers

T2 - Clinical implications

AU - Teoh, Seong Lin

AU - Das, Srijit

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Background: The incidence of lung cancers has increased globally. Increased exposure to tobacco, passive smoking, less consumption of vegetables and fruits and occupational exposure to asbestos, arsenic and chromium are the main risk factors. The pathophysiology of lung cancer is complex and not well understood. Various microRNAs, genes and pathways are associated with lung cancers. The genes involved in lung cancers produce proteins involved in cell growth, differentiation, different cell cycles, apoptosis, immune modulation, tumor spread and progression. The Hippo pathway (also known as the Salvador-Warts-Hippo pathway) is the latest emerging concept in cancers. The Hippo pathway plays an important role in controlling the size of the tissue and organ by virtue of its action on cell proliferation and apoptosis. Objective: In the present review, we highlight the mammalian Hippo pathway, role of its core members, its upstream regulators, downstream effectors and the resistance cases in lung cancers. Results: Specific interaction of Mer with cell surface hyaluronan receptor CD44 is vital in cell contact inhibition, thereby activating Hippo pathway. Both transcription co-activators YAP and TAZ (also known as WWTR1, being homologs of Drosophila Yki) are important regulators of proliferation and apoptosis, and serve as major downstream effectors of the Hippo pathway. Mutation of NF2, the upstream regulator of Hippo pathway is linked to the cancers. Conclusion: Targeting YAP and TAZ may be important for future drug delivery and treatment.

AB - Background: The incidence of lung cancers has increased globally. Increased exposure to tobacco, passive smoking, less consumption of vegetables and fruits and occupational exposure to asbestos, arsenic and chromium are the main risk factors. The pathophysiology of lung cancer is complex and not well understood. Various microRNAs, genes and pathways are associated with lung cancers. The genes involved in lung cancers produce proteins involved in cell growth, differentiation, different cell cycles, apoptosis, immune modulation, tumor spread and progression. The Hippo pathway (also known as the Salvador-Warts-Hippo pathway) is the latest emerging concept in cancers. The Hippo pathway plays an important role in controlling the size of the tissue and organ by virtue of its action on cell proliferation and apoptosis. Objective: In the present review, we highlight the mammalian Hippo pathway, role of its core members, its upstream regulators, downstream effectors and the resistance cases in lung cancers. Results: Specific interaction of Mer with cell surface hyaluronan receptor CD44 is vital in cell contact inhibition, thereby activating Hippo pathway. Both transcription co-activators YAP and TAZ (also known as WWTR1, being homologs of Drosophila Yki) are important regulators of proliferation and apoptosis, and serve as major downstream effectors of the Hippo pathway. Mutation of NF2, the upstream regulator of Hippo pathway is linked to the cancers. Conclusion: Targeting YAP and TAZ may be important for future drug delivery and treatment.

KW - Apoptosis

KW - Cell proliferation

KW - Drug delivery

KW - Genes

KW - Hippo pathway

KW - Lung cancer

UR - http://www.scopus.com/inward/record.url?scp=85040377148&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040377148&partnerID=8YFLogxK

U2 - 10.2174/1389450117666160907153338

DO - 10.2174/1389450117666160907153338

M3 - Review article

VL - 18

SP - 1880

EP - 1892

JO - Current Drug Targets

JF - Current Drug Targets

SN - 1389-4501

IS - 16

ER -